Cetuximab

Curated

← predicts response to

NRAS Mutationother

resistance

Curated

← predicts response to

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

KRAS Exon 2 MutationSNV

resistance

Curated

← predicts response to

ERBB2 Amplificationamplification

4 source records aggregated

resistance

Curated

← predicts response to

4 source records aggregated

resistance

Curated

← predicts response to

BRAF V600

3 source records aggregated

sensitivity

Curated

← predicts response to

3 source records aggregated

sensitivity

Curated

← predicts response to

3 source records aggregated

resistance

Curated

← predicts response to

EGFR Expressionexpression

2 source records aggregated

sensitivity

Curated

← predicts response to

KRAS G12/G13

2 source records aggregated

resistance

Curated

← predicts response to

PIK3CA Mutationother

2 source records aggregated

resistance

Curated

← predicts response to

PTEN Lossdeletion_cna

2 source records aggregated

resistance

Curated

← predicts response to

BRAF Mutationother

2 source records aggregated

resistance

Curated

← predicts response to

EGFR Amplificationamplification

2 source records aggregated

sensitivity

Curated

← predicts response to

NRAS Mutationother

resistance

Curated

← predicts response to

EGFR VIIIdeletion

resistance

Curated

← predicts response to

AREG Expressionexpression

resistance

Curated

← predicts response to

SMAD4 Mutationother

resistance

Curated

← predicts response to

FBXW7 Mutationother

resistance

Curated

← predicts response to

NRAS Q61SNV

resistance

Curated

← predicts response to

KRAS G13SNV

resistance

Curated

← predicts response to

KRAS G12

resistance

Curated

← predicts response to

KRAS G12ASNV

resistance

Curated

← predicts response to

KRAS G12SSNV

resistance

Curated

← predicts response to

KRAS G12CSNV

resistance

Curated

← predicts response to

KRAS A146TSNV

resistance

Curated

← predicts response to

KRAS G12VSNV

resistance

Curated

← predicts response to

KRAS G12DSNV

resistance

Curated

← predicts response to

TP53 Wildtypeother

sensitivity

Curated

← predicts response to

EREG EXPRESSIONexpression

sensitivity

Curated

← predicts response to

AREG Expressionexpression

sensitivity

Curated

← predicts response to

NT5E Overexpressionexpression

sensitivity

Curated

← predicts response to

KRAS Exon 2 MutationSNV

resistance

Curated

← predicts response to

PIK3CA Exon 21 Mutation

resistance

Curated

← predicts response to

TOP1 Amplificationamplification

sensitivity

Curated

← predicts response to

KRAS Q61

resistance

Curated

← predicts response to

resistance

Curated

← predicts response to

ERBB3 Overexpressionexpression

resistance

Curated

← predicts response to

sensitivity

Curated

← predicts response to

NRAS Q179*SNV

resistance

Curated

← predicts response to

NRAS G12DSNV

resistance

Curated

← predicts response to

2 source records aggregated

resistance

Curated

← predicts response to

PIK3CA H1047RSNV

2 source records aggregated

resistance

Curated

← predicts response to

KRAS Q61HSNV

2 source records aggregated

resistance

Curated

← predicts response to

PIK3CA N345KSNV

resistance

Curated

← predicts response to

NRAS G13RSNV

resistance

Curated

← predicts response to

ARAF S490TSNV

resistance

Curated

← predicts response to

KRAS G12VSNV

resistance

Curated

← predicts response to

resistance

Curated

← predicts response to

KRAS G12ASNV

resistance

Curated

← predicts response to

KRAS G12DSNV

resistance

Curated

← predicts response to

KRAS G12SSNV

resistance

Curated

← predicts response to

KRAS G13VSNV

resistance

Curated

← predicts response to

PIK3CA R93WSNV

resistance

Curated

← predicts response to

NRAS Q61HSNV

resistance

Curated

← predicts response to

NRAS Q61RSNV

resistance

Curated

← predicts response to

GNAS R201CSNV

resistance

Curated

← predicts response to

BRAF D594GSNV

resistance

Curated

← predicts response to

PIK3CA S158LSNV

resistance

Curated

← predicts response to

PIK3CA H1047LSNV

resistance

Curated

← predicts response to

KRAS G12RSNV

resistance

Curated

← predicts response to

KRAS Q61KSNV

resistance

Curated

← predicts response to

KRAS Q61RSNV

resistance

Curated

← predicts response to

KRAS Q61LSNV

resistance

Curated

← predicts response to

PIK3CA G1049RSNV

resistance

Curated

← predicts response to

NRAS G12CSNV

resistance

Curated

← predicts response to

KRAS A146PSNV

resistance

Curated

← predicts response to

NRAS Q61KSNV

resistance

Curated

← predicts response to

NRAS Q61LSNV

resistance

Curated

← predicts response to

NRAS G12DSNV

resistance

Curated

Skin Squamous Cell Carcinoma

← predicts response to

EGFR P753SSNV

sensitivity

Curated

← predicts response to

PIK3CA E545KSNV

resistance

Curated

← predicts response to

PIK3CA K966ESNV

resistance

Curated

← predicts response to

PIK3CA V955GSNV

resistance

Curated

← predicts response to

PIK3CA F930SSNV

resistance

Curated

← predicts response to

PIK3CA K944NSNV

resistance

Curated

← predicts response to

PIK3CA V955ISNV

resistance

Curated

← predicts response to

EGFR G465RSNV

resistance

Curated

← predicts response to

EGFR S492RSNV

resistance

Curated

← predicts response to

2 source records aggregated

sensitivity

Curated

← predicts response to

2 source records aggregated

sensitivity

Curated

← predicts response to

PIK3CA Mutationother

resistance

Curated

← predicts response to

BRAF Mutationother

resistance

Curated

← predicts response to

NRAS Mutationother

resistance

Curated

Malignant Head and Neck Neoplasm

← predicts response to

PIK3CA H1047RSNV

sensitivity

Curated

← predicts response to

EGFR R451CSNV

sensitivity

Curated

← predicts response to

BRAF L525RSNV

resistance

Curated

← predicts response to

ERBB2 L755SSNV

resistance

Curated

← predicts response to

ERBB2 V777LSNV

resistance

Curated

Malignant Ovarian Neoplasm

← predicts response to

KRAS G12DSNV

resistance

Curated

← predicts response to

KRAS A146TSNV

resistance

Curated

Malignant Ovarian Neoplasm

← predicts response to

VPS37A Underexpressionexpression

resistance

Curated

← predicts response to

MET Amplificationamplification

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

EGFR K467TSNV

resistance

Curated

← predicts response to

PTP4A3 OVEREXPRESSIONexpression

sensitivity

Curated

← predicts response to

EGF EXPRESSIONexpression

resistance

Curated

← predicts response to

SMAD4 Underexpressionexpression

resistance

Curated

← predicts response to

KRAS G12/G13

resistance

Curated

← predicts response to

KRAS G12RSNV

resistance

Curated

← predicts response to

EGFR S492RSNV

resistance

Curated

← predicts response to

EGFR G719SSNV

sensitivity

Curated

← predicts response to

EGFR G724SSNV

sensitivity

Curated

← predicts response to

NRG1 Expressionexpression

resistance

Curated

← predicts response to

sensitivity

Curated

← predicts response to

KRAS G12VSNV

resistance

Curated

← predicts response to

resistance

Curated

← predicts response to

HRAS G13DSNV

resistance

Curated

← predicts response to

EGFR V441FSNV

resistance

Curated

Cetuximab targets …TARGETS1 of 1
→ targets	EGFR	—	INHIBITOR	—	1	Curated	chembl	graph →

Cetuximab targets …TARGETS1 of 1

→ targets

EGFR

—

INHIBITOR

—

Curated

Cetuximab investigated for …INVESTIGATED_FOR15 of 57show all (up to 200)
→ investigated for	Malignant Colorectal Neoplasmsubtype 5 source records aggregated	supports	A	Malignant Colorectal Neoplasm	5	Curated	civic	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype 53 source records aggregated	supports	B	Malignant Colorectal Neoplasm	53	Curated	civic	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype 2 source records aggregated	supports	B	Head and Neck Squamous Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	Head and Neck Neoplasmcancer_family	unknown	4	Head and Neck Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	4	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Colorectal Neoplasmsubtype	unknown	4	Colorectal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype 38 source records aggregated	supports	C	Malignant Colorectal Neoplasm	38	Curated	civic	graph →
→ investigated for	Skin Squamous Cell Carcinomasubtype	supports	C	Skin Squamous Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Nasopharyngeal Carcinomasubtype	unknown	3	Nasopharyngeal Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	3	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype	unknown	3	Head and Neck Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Colon Neoplasmsubtype	unknown	3	Colon Neoplasm	1	Curated	chembl	graph →
→ investigated for	Pancreatic Neoplasmsubtype	unknown	3	Pancreatic Neoplasm	1	Curated	chembl	graph →
→ investigated for	Rectal Neoplasmsubtype	unknown	3	Rectal Neoplasm	1	Curated	chembl	graph →

Cetuximab investigated for …INVESTIGATED_FOR15 of 57show all (up to 200)

→ investigated for

5 source records aggregated

supports

Curated

→ investigated for

53 source records aggregated

supports

Curated

→ investigated for

Head and Neck Squamous Cell Carcinomasubtype

2 source records aggregated

supports

Curated

→ investigated for

Head and Neck Neoplasmcancer_family

unknown

Head and Neck Neoplasm

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

Squamous Cell Carcinomahistology

unknown

Squamous Cell Carcinoma

Curated

→ investigated for

Colorectal Neoplasmsubtype

unknown

Colorectal Neoplasm

Curated

→ investigated for

38 source records aggregated

supports

Curated

Skin Squamous Cell Carcinoma

→ investigated for

Skin Squamous Cell Carcinomasubtype

supports

Curated

→ investigated for

Nasopharyngeal Carcinomasubtype

unknown

Nasopharyngeal Carcinoma

Curated

→ investigated for

Lung Neoplasmcancer_family

unknown

Lung Neoplasm

Curated

→ investigated for

Head and Neck Squamous Cell Carcinomasubtype

unknown

Curated

→ investigated for

Colon Neoplasmsubtype

unknown

Colon Neoplasm

Curated

→ investigated for

Pancreatic Neoplasmsubtype

unknown

Pancreatic Neoplasm

Curated

→ investigated for

Rectal Neoplasmsubtype

unknown

Rectal Neoplasm

Curated

Cetuximab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 187show all (up to 200)
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 219 trials (50 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	219	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 87 trials (27 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	87	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasmcancer_family 85 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 67 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	67	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasmsubtype 48 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 40 trials (21 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 37 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colon Neoplasm 29 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colon Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Carcinoma 26 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Carcinoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 24 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Rectal Neoplasm 24 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Rectal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Neoplasmcancer_family 22 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Squamous Cell Carcinomahistology 22 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Squamous Cell Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Hypopharyngeal Squamous Cell Carcinoma 20 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hypopharyngeal Squamous Cell Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 20 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	20	Observed	clinicaltrials	graph →

Cetuximab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 187show all (up to 200)

→ investigated in trials for

219 trials (50 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

219

Observed

→ investigated in trials for

Head and Neck Squamous Cell Carcinomasubtype

87 trials (27 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Head and Neck Neoplasm

→ investigated in trials for

Malignant Head and Neck Neoplasmcancer_family

85 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Lung Non-Small Cell Carcinoma

→ investigated in trials for

67 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Small Cell Carcinoma

Observed

→ investigated in trials for

Colorectal Neoplasmsubtype

48 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Colorectal Neoplasm

Observed

→ investigated in trials for

40 trials (21 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Malignant Neoplasm

37 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

→ investigated in trials for

Malignant Colon Neoplasm

29 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colon Neoplasm

Observed

→ investigated in trials for

Colorectal Carcinoma

26 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Colorectal Carcinoma

Observed

Malignant Pancreatic Neoplasm

→ investigated in trials for

24 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Pancreatic Neoplasm

Observed

Malignant Rectal Neoplasm

→ investigated in trials for

24 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Rectal Neoplasm

Observed

→ investigated in trials for

Head and Neck Neoplasmcancer_family

22 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Head and Neck Neoplasm

Observed

→ investigated in trials for

Squamous Cell Carcinomahistology

22 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Squamous Cell Carcinoma

Observed

Hypopharyngeal Squamous Cell Carcinoma

→ investigated in trials for

20 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hypopharyngeal Squamous Cell Carcinoma

Observed

Malignant Esophageal Neoplasm

→ investigated in trials for

20 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Esophageal Neoplasm

Observed

Malignant Head and Neck Neoplasm

Cetuximab studied in …STUDIED_INderived10 of 782show all (up to 200)
→ studied in	NCT03358472Phase 3 · completed Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) · 782 trials list this drug (154 active)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04717375Phase 1/Phase 2 · terminated Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors · 782 trials list this drug (154 active)	—	—	Neoplasm,Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · 782 trials list this drug (154 active)	—	—	Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06865664Phase 1 · recruiting FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma · 782 trials list this drug (154 active)	—	—	Rhabdomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07030959Phase 1 · recruiting Study of AUBE00 in Patients With Solid Tumors · 782 trials list this drug (154 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07659795Phase 2 · recruiting A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer · 782 trials list this drug (154 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07672483Phase 1 · not yet recruiting IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors · 782 trials list this drug (154 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04793958Phase 3 · active not recruiting Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) · 782 trials list this drug (154 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06997497Phase 3 · recruiting A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) · 782 trials list this drug (154 active)	—	—	Colon Adenocarcinoma,Rectal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07286149Phase 1/Phase 2 · recruiting A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · 782 trials list this drug (154 active)	—	—	Lung Neoplasm	1	Observed	clinicaltrials	graph →

Cetuximab studied in …STUDIED_INderived10 of 782show all (up to 200)

→ studied in

NCT03358472Phase 3 · completed

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) · 782 trials list this drug (154 active)

—

Observed

Neoplasm,Malignant Neoplasm

→ studied in

NCT04717375Phase 1/Phase 2 · terminated

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors · 782 trials list this drug (154 active)

—

Observed

Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2

→ studied in

NCT06589804Phase 3 · recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · 782 trials list this drug (154 active)

—

Observed

→ studied in

NCT06865664Phase 1 · recruiting

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma · 782 trials list this drug (154 active)

—

Rhabdomyosarcoma

Observed

→ studied in

NCT07030959Phase 1 · recruiting

Study of AUBE00 in Patients With Solid Tumors · 782 trials list this drug (154 active)

—

Observed

→ studied in

NCT07659795Phase 2 · recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer · 782 trials list this drug (154 active)

—

Observed

→ studied in

NCT07672483Phase 1 · not yet recruiting

IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors · 782 trials list this drug (154 active)

—

not mapped

Observed

→ studied in

NCT04793958Phase 3 · active not recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) · 782 trials list this drug (154 active)

—

Observed

Colon Adenocarcinoma,Rectal Adenocarcinoma

→ studied in

NCT06997497Phase 3 · recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) · 782 trials list this drug (154 active)

—

Observed

→ studied in

NCT07286149Phase 1/Phase 2 · recruiting

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · 782 trials list this drug (154 active)

—

Lung Neoplasm

Observed